bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 65.6% in December

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 51,967 shares, an increase of 65.6% from the December 15th total of 31,376 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 82,366 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 82,366 shares, the short-interest ratio is presently 0.6 days. Approximately 1.2% of the shares of the company are short sold.

Hedge Funds Weigh In On bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Scientech Research LLC purchased a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned 0.46% of bioAffinity Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.64% of the company’s stock.

Wall Street Analysts Forecast Growth

BIAF has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of bioAffinity Technologies to a “strong sell” rating in a report on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF opened at $1.37 on Friday. The company has a current ratio of 3.65, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $6.17 million, a P/E ratio of -0.07 and a beta of 2.45. The firm has a 50 day moving average of $1.45 and a 200-day moving average of $4.63. bioAffinity Technologies has a 1 year low of $1.11 and a 1 year high of $46.53.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, November 14th. The company reported ($2.70) EPS for the quarter, meeting analysts’ consensus estimates of ($2.70). bioAffinity Technologies had a negative return on equity of 425.87% and a negative net margin of 217.45%.The firm had revenue of $1.45 million for the quarter, compared to analyst estimates of $1.41 million.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.